Comprehensive review on Alzheimer's disease: causes and treatment
Z Breijyeh, R Karaman - Molecules, 2020 - mdpi.com
Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and
it is the main cause of dementia, which is characterized by a decline in thinking and …
it is the main cause of dementia, which is characterized by a decline in thinking and …
Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade
Peptides and proteins have been found to possess an inherent tendency to convert from
their native functional states into intractable amyloid aggregates. This phenomenon is …
their native functional states into intractable amyloid aggregates. This phenomenon is …
Cannabinoids: therapeutic use in clinical practice
Medical case reports suggest that cannabinoids extracted from Cannabis sativa have
therapeutic effects; however, the therapeutic employment is limited due to the psychotropic …
therapeutic effects; however, the therapeutic employment is limited due to the psychotropic …
[HTML][HTML] Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease
H Zhang, W Wei, M Zhao, L Ma, X Jiang… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …
Iron homeostasis disorder and Alzheimer's disease
Y Peng, X Chang, M Lang - International journal of molecular sciences, 2021 - mdpi.com
Iron is an essential trace metal for almost all organisms, including human; however,
oxidative stress can easily be caused when iron is in excess, producing toxicity to the human …
oxidative stress can easily be caused when iron is in excess, producing toxicity to the human …
Epigallocatechin-3-Gallate (EGCG): New therapeutic perspectives for neuroprotection, aging, and neuroinflammation for the modern age
A Payne, S Nahashon, E Taka, GM Adinew… - Biomolecules, 2022 - mdpi.com
Alzheimer's and Parkinson's diseases are the two most common forms of neurodegenerative
diseases. The exact etiology of these disorders is not well known; however, environmental …
diseases. The exact etiology of these disorders is not well known; however, environmental …
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases
T Efferth, F Oesch - Medicinal research reviews, 2021 - Wiley Online Library
The sesquiterpene lactone artemisinin from Artemisia annua L. is well established for
malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a …
malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a …
[HTML][HTML] Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ …
Z He, X Li, Z Wang, Y Cao, S Han, N Li, J Cai, S Cheng… - Redox Biology, 2023 - Elsevier
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the
deposition of β-amyloid (Aβ) peptides and dysfunction of mitochondrion, which result in …
deposition of β-amyloid (Aβ) peptides and dysfunction of mitochondrion, which result in …
Aducanumab therapy to treat Alzheimer's disease: a narrative review
Background. Aducanumab, a new monoclonal antibody that targets β‐amyloid aggregates,
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer's disease therapy
Toxic aggregated amyloid-β accumulation is a key pathogenic event in Alzheimer's disease
(AD), which derives from amyloid precursor protein (APP) through sequential cleavage by …
(AD), which derives from amyloid precursor protein (APP) through sequential cleavage by …